Advanced Pacemaker Diagnostic Features in the Characterization of Atrial Fibrillation: Impact on Preventive Pacing Algorithms

YANG, A., et al .: Advanced Pacemaker Diagnostic Features in the Characterization of Atrial Fibrillation: Impact on Preventive Pacing Algorithms. Pacing algorithms to prevent PAF are mainly based on the suppression of premature atrial complexes (PACs), which play an important role in its initiation. In contrast to 24-hour ambulatory electrocardiograms, advanced pacemaker (PM) diagnostic features are capable of recording AF episodes during long follow-up periods and of characterizing AF in a detailed fashion. For the specific use of these algorithms, a detailed characterization of AF was performed in 91 dual chamber PM recipients with histories of AF. Fifteen patients with episodes of oversensing due to far-field signals or frequent episodes of "2:1-undersensing" of atrial flutter were excluded. The remaining 76 patients had high recurrence rates of AF (median 0.8 episodes/day), however, the majority of episodes lasted <7 minutes. Despite frequent PACs (median 10.8/hour) during sinus rhythm, a median of 66.4% of the AF episodes were preceded by <2 PACs/min before onset. In conclusion, frequent, short-lived AF episodes seem best suited for AF preventive pacing therapies. However, the small number of PACs preceding many AF episodes may limit the efficacy of PAC suppressing algorithms. (PACE 2003; 26[Pt. II]:310–313)     

Simultaneous Recordings of the Monophasic Action Potential with Silver Chloride- and Ir-Coated Electrodes

Ag AgCI and Ir-coated electrodes allow the recording of the monophasic action potential (MAP) due to their electrical properties like non-polarisability. This study investigates the correlation of MAP recorded with both types of electrodes. In 20 mongrel dogs (18 ± 6 kg) an Ag/AgCI and an Ir-coated catheter (Ir) were placed endo-cardially in the apex of the right ventricle. The effects of isoproterenol and verapamil were investigated during spontaneous rhythm and stimulation simultaneously recorded with both types of electrodes in 10 dogs without AV-node ablation. The correlation at different heart rates were investigated in 10 other dogs with complete AV-block. The morphology and amplitudes of MAP were comparable (AgCl: 15±7 mV; Ir: 13±8 mV). Following an i.v. bolus of 2μg/kg isoproterenol the spontaneous rate increased (175±18 to 245±25 bpm). During stimulation with 250 ms cycle length the duration shortened (MAPd90: AgCl: 160 ± 11 to 130 ± 12 ms; Ir: 154 ± 18 to 128±15 ms). The alterations reversed after 20 mm. An i.v. bolus of 0.2 mg/kg verapamil decreased the spontaneous rate (167±11 to 104 ± 23 bpm) and lengthened the MAPd90 (AgCl: 182 ± 14 to 220±13 ms; Ir: 174 ± 16 to 216, 21 ms) at 300 ms stimulation. The correlation between the MAPd90 of both lead types was r=0.98 during all measurements. Under the effect of beta-agonist and Ca²⁺ -antagonist medication MAP showed a strong correlation recorded with both types of electrodes. Thus, both leads allow the recording of MAP but only the Ir-electrodes with their long-term stability are implantable and allows us to control the effects of drugs with implantable devices.     

A cost analysis comparing erythropoietin and red cell transfusions in the treatment of anemia of prematurity

BACKGROUND: Anemia of prematurity is invariably observed in very low birth weight infants and may become symptomatic enough to be treated with packed red cell transfusions. Recently, treatment of this condition with recombinant human erythropoietin has been advocated. STUDY DESIGN AND METHODS: To compare the costs of training symptomatic anemia in hospitalized premature infants with transfusions alone or with erythropoietin plus red cell transfusions as needed, cost estimates were derived from local hospital and published cost data. Decision analysis and sensitivity analysis were applied to a "base case." The base case was derived from results of a multicenter erythropoietin trial in the United States in which premature infants received 500 U of erythropoietin per kg of body weight each week. Because erythropoietin treatment began on average at 3 weeks of life, when infants were clinically stable, they had already received 3.5 red cell transfusions. During the 6-week treatment period, erythropoietin- treated infants received significantly fewer additional transfusions: a mean of 1.6 versus 1.1. RESULTS: The base-case cost in 1993 dollars for treating anemia in hospitalized premature infants with erythropoietin and transfusions was $1,326. This was nearly twice the cost of conventional treatment with transfusions alone ($721). If the 6-week treatment period alone is considered, erythropoietin is 3.6 times more costly: $840 versus $235. CONCLUSION: The largest available US study using erythropoietin to treat anemia in premature infants has demonstrated a small, but significant, reduction in transfusion needs. However, this study's cost data alone do not justify the widespread use of erythropoietin in premature infants. When this issue is probed in great depth, sensitivity analyses demonstrate that major reductions in erythropoietin's cost and/or improvements in its effectiveness quite possibly will make its use economically more attractive.     

Donation reactions among autologous donors

Studies of risk factors associated with reactions among autologous blood donors have been limited. Therefore, 2091 autologous and 4737 homologous donations were examined. Donors at greatest risk for reaction were autologous donors who had reactions at first donation; among 45 who made repeat donations for the same surgery, 17 (38%) had repeat reactions. The group least likely to experience reactions were the autologous donors greater than or equal to 66 years old; they experienced a 1.9 greater than or equal to percent (6/310) incidence of reactions. More reactions were seen in both autologous and homologous donors in the categories of first-time donor, female gender, decreasing age, and lower weight. Multiple logistic regression analysis showed that all of these variables were independent predictors of donor reaction, with first-time donation (odds ratio, 2.4) and female gender (odds ratio, 1.9) being the strongest predictors of reaction. Donor room personnel should be alerted that autologous donors who react at first donation are very likely to react at subsequent donations. Contrary to common concern, elderly autologous donors are least likely to have reactions.     

Comparison of autosurge versus surge protocols for discontinuous-flow centrifugation plateletapheresis

Autosurge is a new, highly automated protocol for collecting platelets by centrifugation plateletapheresis. It was developed to allow optimal cell collections with less operator effort than was required with the earlier, standard Surge protocol. The authors compared the cellular content of 201 platelet concentrates prepared by Surge with that of 120 concentrates prepared by Autosurge by the same group of operators, using the same cell separator. Platelet yields were similar (p = 0.775) for both protocols (mean X 10(-11) were 3.54 and 3.57 for Surge and Autosurge, respectively) and when subdivided according to preapheresis donor blood platelet counts, hematocrits, and leukocyte counts. Although platelet yields were comparable in concentrates prepared by either protocol, high donor hematocrit had less adverse effect on platelet yield when the Autosurge protocol was used. The composition of concentrates differed between protocols in that leukocytes contamination was significantly less (p less than 0.001) in units collected by Autosurge (3.4 X 10(8)) than in those collected by Surge (5.8 X 10(8)). Operator involvement can be less intense with Autosurge because the protocol includes automatic adjustment of cell separator settings for optimal plateletapheresis. The results of the direct comparison study were confirmed by data from 509 additional plateletapheresis procedures performed during routine blood center operation. Autosurge should replace Surge because the former easily produces platelet concentrates that contain fewer leukocytes without compromising platelet yields.     

Transfusion-transmitted babesiosis: a case report from a new endemic area

The seventh documented case of babesiosis transmitted by transfusion is reported. Both the donor and the recipient are residents of Connecticut, where the presence of endemic babesiosis has only recently been established. As the range of Babesia microti, and its vector the Ixodes dammini tick, continues to expand, clinicians and blood bank directors should be aware that cases of transfusion-transmitted babesiosis may occur in newly endemic areas.     

Lymph node mapping in the mouse

Accurate identification of lymph nodes in the mouse is critical for studies of tumor metastasis, and of regional immune responses following immunization. However, these small lymphatic organs are often difficult to identify in mice using standard dissection techniques, so that larger rats have been used to characterize rodent lymphatic drainage. We developed techniques injecting dye into the mouse footpad or tail, to label the lymphatic drainage of the hind leg and flank, pelvic viscera, prostate and mammary glands. While lymphatic drainage patterns were similar in mice and rats, the inguinal lymph nodes showed distinct differences in afferent and efferent drainage. These techniques allow accurate and rapid identification of lymph nodes and lymphatic drainage in normal as well as diseased mice.     

新烯二炔类大分子抗肿瘤抗生素C1027的分子构成与活性关系

C1027是含烯二炔发色团的大分子肽类新抗肿瘤抗生素,由一个蛋白和一个烯二炔发色团两部分构成。后者是活性部分,对肿瘤细胞有强杀伤作用,蛋白对发色团的活性有保护作用。蛋白和发色团在一定条件下可以重新组建成完整的C1027。C1027分子内的二硫键有辅助蛋白保护发色团的作用,当二硫键被还原后,C1027活性丢失加快。C1027被链霉蛋白酶降解产生一个分子量为3～5kDa的中间产物,此产物对肿瘤细胞的杀伤作用与完整C1027相同,表明C1027是可以裁剪的,保护发色团的最小肽段为3～5kDa。